1. Home
  2. AKRO vs ENLT Comparison

AKRO vs ENLT Comparison

Compare AKRO & ENLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • ENLT
  • Stock Information
  • Founded
  • AKRO 2017
  • ENLT 2008
  • Country
  • AKRO United States
  • ENLT Israel
  • Employees
  • AKRO N/A
  • ENLT N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • ENLT
  • Sector
  • AKRO Health Care
  • ENLT
  • Exchange
  • AKRO Nasdaq
  • ENLT Nasdaq
  • Market Cap
  • AKRO 3.9B
  • ENLT 2.7B
  • IPO Year
  • AKRO 2019
  • ENLT 2023
  • Fundamental
  • Price
  • AKRO $51.69
  • ENLT $25.10
  • Analyst Decision
  • AKRO Strong Buy
  • ENLT Buy
  • Analyst Count
  • AKRO 6
  • ENLT 3
  • Target Price
  • AKRO $82.50
  • ENLT $19.67
  • AVG Volume (30 Days)
  • AKRO 1.6M
  • ENLT 48.6K
  • Earning Date
  • AKRO 08-08-2025
  • ENLT 08-06-2025
  • Dividend Yield
  • AKRO N/A
  • ENLT N/A
  • EPS Growth
  • AKRO N/A
  • ENLT 90.47
  • EPS
  • AKRO N/A
  • ENLT 0.98
  • Revenue
  • AKRO N/A
  • ENLT $397,296,000.00
  • Revenue This Year
  • AKRO N/A
  • ENLT $355.90
  • Revenue Next Year
  • AKRO N/A
  • ENLT $42.83
  • P/E Ratio
  • AKRO N/A
  • ENLT $24.84
  • Revenue Growth
  • AKRO N/A
  • ENLT 44.42
  • 52 Week Low
  • AKRO $21.34
  • ENLT $14.01
  • 52 Week High
  • AKRO $58.40
  • ENLT $26.27
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 45.35
  • ENLT 66.62
  • Support Level
  • AKRO $50.13
  • ENLT $24.60
  • Resistance Level
  • AKRO $53.60
  • ENLT $26.27
  • Average True Range (ATR)
  • AKRO 2.03
  • ENLT 0.52
  • MACD
  • AKRO -0.83
  • ENLT 0.12
  • Stochastic Oscillator
  • AKRO 6.37
  • ENLT 76.36

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

About ENLT Enlight Renewable Energy Ltd.

Enlight Renewable Energy Ltd develops, finances, constructs, owns, and operates utility-scale renewable energy projects. The company's operating segments are the MENA segment, Europe segment, U.S.A segment, and Others. It generates the majority of its revenue from the Europe segment, which produces its revenue from the sale of the electricity that is produced through wind energy and solar energy in Europe.

Share on Social Networks: